Breaking News Instant updates and real-time market news.

GSAT

Globalstar

$1.47

0.04 (2.80%)

, XOMA

Xoma

$5.50

-0.17 (-3.00%)

09:09
12/22/16
12/22
09:09
12/22/16
09:09

On The Fly: Pre-market Movers

HIGHER: Globalstar (GSAT), up 23.1% after TRDaily reported, citing sources, that the company's revised FCC TLPS proposal has received at least three votes at the FCC... XOMA (XOMA), up 14.4% after it said it will sell royalty streams, cut 57 positions, and named Jim Neal chief executive officer to replace John Varian... Tokai Pharmaceuticals (TKAI), up 40.6% after announcing that Otic Pharma and its shareholders will become the majority owners of the company... Micron (MU), up 12.5% after reporting quarterly results. DOWN AFTER EARNINGS: Bed Bath & Beyond (BBBY), down 4%... Red Hat (RHT), down 12.1%... CalAmp (CAMP), down 3.4%. ALSO LOWER: OvaScience (OVAS), down 29.3% after it announced a business update under which Chief Executive Officer Harald Stock and Chief Operating Officer Paul Chapman will step down and under which the company will cut roughly 30% of its workforce.

GSAT

Globalstar

$1.47

0.04 (2.80%)

XOMA

Xoma

$5.50

-0.17 (-3.00%)

TKAI

Tokai Pharmaceuticals

MU

Micron

$20.58

-0.07 (-0.34%)

BBBY

Bed Bath & Beyond

$45.56

-0.64 (-1.39%)

RHT

Red Hat

$79.79

0.4 (0.50%)

CAMP

CalAmp

$15.73

0.19 (1.22%)

OVAS

OvaScience

$2.97

-0.02 (-0.67%)

  • 15

    Jan

GSAT Globalstar
$1.47

0.04 (2.80%)

06/13/16
CHDN
06/13/16
DOWNGRADE
CHDN
Neutral
Globalstar downgraded to Neutral from Buy at Chardan
06/13/16
CHDN
06/13/16
DOWNGRADE
CHDN
Neutral
Globalstar downgraded on lower odds of TLPS passing at Chardan
As previously reported, Chardan downgraded Globalstar to Neutral from Buy, as analyst James McIlree argues that the odds of TLPS passing have diminished greatly after one FCC commissioner announced he had voted against the TLPS proposal and reports indicated that another also voted against TLPS. Even if TLPS does pass it seems it will be a provisional approval, or for test period, which would be a positive step but would also make it more difficult for the company to attract partners, McIlree tells investors.
XOMA Xoma
$5.50

-0.17 (-3.00%)

11/14/16
WEDB
11/14/16
DOWNGRADE
Target $14
WEDB
Neutral
XOMA downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Liana Moussatos downgraded XOMA to Neutral and lowered its price target to $14 from $17 in anticipation of dilutive financing before Q2 2017. The analyst said XOMA expects $10M from a milestone payment and hopes to out-license an IL 2 immuno-oncology antibody within the next few months potentially providing non-dilutive capital; but Moussatos still believes the company needs additional financing through 2017 and anticipates near-term dilutive financing of about $50M.
03/10/16
PIPR
03/10/16
NO CHANGE
Target $0.85
PIPR
Neutral
XOMA price target lowered to 85c from $1.85 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for XOMA to 85c after removing gevokizumab from his model. The company has cash through Q1 of 2017 and a sale of gevokizumab could extend the runway further, Tenthoff tells investors in a post-earnings research note. He keeps a Neutral rating on XOMA following the company's Q4 results.
TKAI Tokai Pharmaceuticals

07/26/16
WBLR
07/26/16
DOWNGRADE
WBLR
Market Perform
Tokai Pharmaceuticals downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Tokai Pharmaceuticals after the company announced plans to discontinue its prostate cancer clinical trial.
07/28/16
BOFA
07/28/16
DOWNGRADE
BOFA
Underperform
Tokai Pharmaceuticals downgraded to Underperform from Neutral at BofA/Merrill
07/26/16
STFL
07/26/16
DOWNGRADE
STFL
Hold
Tokai Pharmaceuticals downgraded to Hold from Buy at Stifel
07/26/16
BMOC
07/26/16
DOWNGRADE
BMOC
Market Perform
Tokai Pharmaceuticals downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgraded Tokai Pharmaceuticals after the company announced plans to discontinue its prostate cancer clinical trial.
MU Micron
$20.58

-0.07 (-0.34%)

12/22/16
JPMS
12/22/16
NO CHANGE
Target $28
JPMS
Overweight
Micron price target raised to $28 from $25 at JPMorgan
JPMorgan analyst Harlan Sur raised his price target for Micron Technology to $28 saying the company's margins are inflecting better than expected following its "strong" Q2 results. The analyst continues to see upside in the shares and keeps an Overweight rating on Micron.
12/22/16
BMUR
12/22/16
NO CHANGE
Target $28
BMUR
Buy
Micron price target raised to $28 from $25 at Brean Capital
Brean Capital analyst Mike Burton raised his price target on Micron to $28 from $25 following the company's Q1 report. The analyst noted Micron beat on both sales and earnings and said the company remains in the midst of a positive cycle in the DRAM and NAND markets. Burton reiterated his Buy rating on Micron shares.
12/22/16
12/22/16
UPGRADE
Target $33

Buy
Micron upgraded to Buy after results at Needham
As previously reported, Needham analyst Rajvindra Gill upgraded Micron to Buy from Underperform, with a $33 price target, following the company's "significant beat and raise" this quarter. The analyst believes Micron has regained its customer positioning in 20nm, is successfully migrating to 3D NAND and is benefiting from a substantially better pricing environment in DRAM.
12/22/16
CRSS
12/22/16
UPGRADE
CRSS
Buy
Micron upgraded to Buy from Hold at Cross Research
BBBY Bed Bath & Beyond
$45.56

-0.64 (-1.39%)

06/23/16
OPCO
06/23/16
NO CHANGE
OPCO
Perform
Bed Bath & Beyond continues to struggle, says Oppenheimer
Oppenheimer analyst Brian Nagel says Bed Bath & Beyond's weaker than expected Q1 results and more downbeat fiscal year 2016 outlook reflect ongoing struggles at the company. While the analyst remains optimistic that over the longer term Bed, Bath & Beyond will find the right formula to compete effectively online while protecting industry leading margins, he expects the current transition at the company to persist for a while and fuel choppiness in results. Nagel reiterates a Perform rating on the shares.
12/20/16
12/20/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Amgen (AMGN) downgraded to Neutral from Outperform at Credit Suisse with analyst Alethia Young saying she has a lower conviction in the base business and sees limited upside to positive PCSK9 outcomes in the first quarter of 2017 given high expectations. 2. Bed Bath & Beyond (BBBY) downgraded to Underperform from Neutral at Cleveland Research with analyst Daryl Boehringer citing checks that indicate comp trends remain "uninspiring" given declining traffic, online migration, lack of market share gains. 3. Sibanye Gold (SBGL) downgraded to Sell from Hold at Deutsche Bank with analyst Patrick Mann saying he expects a "challenging" 2017 for the company as EBITDA declines. 4. Cempra (CEMP) downgraded to Sell from Buy at SunTrust with analyst Edward Nash saying says he expects the FDA to provide complete response letters for the company's solithromycin treatment due to manufacturing issues. 5. Acuity Brands (AYI) downgraded to Neutral from Outperform at Baird with analyst Timothy Wojs saying he believes a near-term demand lull could keep the stock range bound over the next couple of quarters, leaving a thin margin for error. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/16
CLVD
12/20/16
DOWNGRADE
CLVD
Underperform
Bed Bath & Beyond downgraded to Underperform from Neutral at Cleveland Research
Cleveland Research analyst Daryl Boehringer downgraded Bed Bath & Beyond to Underperform following checks that indicate comp trends remain "uninspiring" given declining traffic, online migration, lack of market share gains. The analyst sees Q3 comps flat to slightly below consensus of +.4% and continues to see comp risk over the near-term and said it appears traffic has slowed noticeably over the last six weeks.
12/22/16
RAJA
12/22/16
DOWNGRADE
RAJA
Market Perform
Bed Bath & Beyond downgraded to Market Perform from Strong Buy at Raymond James
Raymond James analyst Budd Bugatch downgraded Bed Bath & Beyond to Market Perform from Strong Buy following the Q3 sales and earnings miss. The analyst said Bed Bath still has a long runway ahead before it realizes benefits from technology investments, membership program, and recent investments in One Kings Lane and PMall.com. Bugatch recommends moving to the sidelines until gross margins and operating expenses stabilize and the benefits of incremental investments are quantifiable.
RHT Red Hat
$79.79

0.4 (0.50%)

12/22/16
STFL
12/22/16
DOWNGRADE
Target $70
STFL
Hold
Red Hat downgraded to Hold from Buy at Stifel
Stiflel analyst Brad Reback downgraded Red Hat to Hold and lowered its price target to $70 from $87 citing the disappointing Q3 report. Billings growth of $679.4M grew only 8.7% year-over-year-CC, the lowest CC billings growth rate in at least 11 quarters, the analyst wrote. Reback is increasingly concerned that emerging areas of OpenStack and OpenShift are likely to remain niche products, combined with the "explosive" growth by hyperscale clout providers, is likely to limit Red Hat's future upside.
12/22/16
BMOC
12/22/16
DOWNGRADE
BMOC
Market Perform
Red Hat downgraded to Market Perform from Outperform at BMO Capital
12/15/16
OTRG
12/15/16
NO CHANGE
OTRG
Red Hat re-sellers mostly met or exceeded Q3 expectations, says OTR Global
12/22/16
OPCO
12/22/16
NO CHANGE
Target $88
OPCO
Outperform
Oppenheimer remains positive on Red Hat after results
After Red Hat reported mixed results/guidance, Oppenheimer analyst Ittai Kidron notes that "one quarter does not make a trend," and the weakness appears largely due to a combination of a number of factors, none of which he believes reflect on the company's longer term business outlook. The analyst maintains his positive view, with deals metrics "largely solid" despite delayed government deals, and says he still sees upside as Red Hat drives continued expansion through up-sell opportunities. He reiterates an Outperform rating and $88 price target on the shares.
CAMP CalAmp
$15.73

0.19 (1.22%)

09/30/16
ADAM
09/30/16
NO CHANGE
Target $25
ADAM
Buy
Canaccord keeps Buy rating, $25 target on CalAmp despite MRM weakness
Canaccord analyst T. Michael Walkley noted that CalAmp reported lower than expected Q2 revenue and EPS gave worse than expected guidance citing soft MRM product trends in North America, but he maintains his Buy rating and $25 price target on the stock, contending that the company's LoJack acquisition provides a strong brand and channel to drive longer-term growth. CalAmp shares, which were downgraded to Equal-Weight at First Analysis following the company's quarterly report, are down nearly 15% in pre-market trading to $14 per share.
10/31/16
MACQ
10/31/16
INITIATION
Target $14
MACQ
Neutral
CalAmp initiated with a Neutral at Macquarie
Macquarie analyst Andrew DeGasperi initiated CalAmp with a Neutral and a $14 price target.
09/30/16
09/30/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alcobra (ADHD) downgraded to Neutral from Overweight at Piper Jaffray analyst Charles Duncan citing the near-term increase in clinical risk and timeline uncertainty after the company's Metadoxine program was placed on full clinical hold by the FDA. 2. CNO Financial (CNO) downgraded to Neutral from Buy at Goldman and to Neutral from Buy at BTIG. 3. CalAmp (CAMP) downgraded to Equal-Weight from Overweight at First Analysis with analyst Howard Smith saying the shares are likely range-bound until the company can build investor confidence in its growth profile. 4. Knoll (KNL) downgraded to Market Perform from Outperform at Raymond James with analyst Budd Bugatch citing the reports from office furniture manufacturers and residential furniture retailers that indicate business activity slowed in July and only modestly recovered in August and September. 5. Core-Mark (CORE) downgraded to Hold from Buy at Jefferies saying he sees earnings risk in 2017 following the loss of Circle K's Southeast. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
AGIS
10/03/16
DOWNGRADE
AGIS
Hold
CalAmp downgraded to Hold from Buy at Aegis
OVAS OvaScience
$2.97

-0.02 (-0.67%)

01/21/16
01/21/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3M (MMM) initiated with a Buy at Citi... AMAG Pharmaceuticals (AMAG) initiated with an Equal Weight at Barclays... Acceleron (XLRN) initiated with an Outperform at Credit Suisse... Agios Pharmaceuticals (AGIO) initiated with an Outperform at Credit Suisse... Akebia (AKBA) initiated with a Neutral at Credit Suisse... CIT Group (CIT) initiated with a Hold at Deutsche Bank... Check Point (CHKP) initiated with a Neutral at Cleveland Research... Clovis (CLVS) initiated with an Outperform at Credit Suisse... Colfax (CFX) initiated with a Sell at Citi... Danaher (DHR) initiated with a Neutral at Citi... Dover (DOV) initiated with a Neutral at Citi... Emerson (EMR) initiated with a Sell at Citi... Endo (ENDP) initiated with an Equal Weight at Barclays... Endocyte (ECYT) initiated with an Outperform at Credit Suisse... FibroGen (FGEN) initiated with a Neutral at Credit Suisse... FireEye (FEYE) initiated with an Outperform at Northland... Five Prime (FPRX) initiated with an Outperform at Credit Suisse... Flowserve (FLS) initiated with a Neutral at Citi... General Electric (GE) initiated with a Buy at Citi... Honeywell (HON) initiated with a Buy at Citi... Ignyta (RXDX) initiated with an Outperform at Credit Suisse... Illinois Tool Works (ITW) initiated with a Buy at Citi... Imperva (IMPV) initiated with an Outperform at Northland... Ingersoll-Rand (IR) initiated with a Buy at Citi... Joint Corp. (JYNT) initiated with a Buy at Maxim... M&T Bank (MTB) resumed with a Neutral at JPMorgan... Medivation (MDVN) initiated with an Outperform at Credit Suisse... Newfield Exploration (NFX) initiated with an Outperform at Imperial Capital... OvaScience (OVAS) initiated with an Underperform at Credit Suisse... PFSweb (PFSW) initiated with a Buy at Canaccord... Palo Alto (PANW) initiated with an Outperform at Northland... Perrigo (PRGO) initiated with an Overweight at Barclays... Prothena (PRTA) initiated with an Outperform at Credit Suisse... Puma Biotechnology (PBYI) initiated with an Outperform at Credit Suisse... Rockwell Automation (ROK) initiated with a Neutral at Citi... Seattle Genetics (SGEN) initiated with an Outperform at Credit Suisse... Shopify (SHOP) initiated with an Outperform at Wedbush... Square (SQ) initiated with a Market Perform at William Blair... TESARO (TSRO) initiated with an Outperform at Wedbush... Tyco (TYC) initiated with a Neutral at Citi... Ultragenyx (RARE) initiated with an Outperform at Credit Suisse.
01/25/16
01/25/16
DOWNGRADE

On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Eagle (AEO) downgraded to Hold from Buy at BB&T... American Express (AXP) downgraded on weak revenue outlook at Argus... Bristol-Myers (BMY) downgraded to Market Perform from Outperform at BMO Capital... Caterpillar (CAT) downgraded to Sell from Neutral at Goldman... Crestwood Equity (CEQP) downgraded to Neutral on potential distribution cut at Baird... Cummins (CMI) downgraded to Neutral from Buy at Citi... Federal Realty (FRT) downgraded to Hold from Buy at Evercore ISI... GKN PLC (GKNLY) downgraded to Neutral from Outperform at Credit Suisse... Galapagos NV (GLPG) downgraded to Neutral from Buy at GoldmanvHortonworks (HDP) downgraded to Perform from Outperform at Oppenheimer... International Flavors (IFF) downgraded on headwinds at Stifel... International Paper (IP) downgraded to Neutral from Buy at Citi... JPMorgan (JPM) downgraded to Neutral from Buy at Nomura... KapStone (KS) downgraded to Underperform from Neutral at Macquarie... Mosaic (MOS) downgraded to Neutral from Overweight at JPMorgan... NetSuite (N) downgraded to Equal Weight from Overweight at Stephens... ONEOK Partners (OKS) downgraded to Neutral at Baird... OvaScience (OVAS) downgraded to Perform from Outperform at Oppenheimer... Packaging Corp. (PKG) downgraded to Neutral from Buy at Citi... Potash (POT) downgraded to Neutral from Overweight at JPMorgan... Power Solutions (PSIX) downgraded to Neutral from Overweight at Piper Jaffray... Raymond James (RJF) downgraded to Neutral from Buy at Nomura... Regeneron (REGN) downgraded to Sell from Neutral at Chardan... SanDisk (SNDK) downgraded to Underperform from Outperform at CLSA... Toll Brothers (TOL) downgraded to Market Perform from Outperform at JMP Securities... Twitter (TWTR) downgraded to Hold from Buy at Stifel... WPX Energy (WPX) downgraded to Sector Perform from Outperform at Iberia... WestRock (WRK) downgraded to Neutral from Buy at BofA/Merrill... Whole Foods (WFM) downgraded to Underperform from Market Perform at BMO Capital... Zurich Insurance (ZURVY) downgraded to Neutral from Outperform at Exane BNP Paribas.
01/25/16
OPCO
01/25/16
DOWNGRADE
OPCO
Perform
OvaScience downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Rohit Vanjani downgraded OvaScience to Perform saying realizing the opportunity for the company's first launched technology, AUGMENT, may take some time. AUGMENT traction may continue to be challenged in 2016, Vanjani tells investors in a research note.
12/07/16
OPCO
12/07/16
INITIATION
OPCO
Perform
OvaScience assumed with a Perform at Oppenheimer
Oppenheimer analyst Derek Archila assumed coverage of OvaScience with a Perform rating citing a lack of revenue visibility.

TODAY'S FREE FLY STORIES

KSU

Kansas City Southern

$105.80

-0.07 (-0.07%)

17:45
08/18/17
08/18
17:45
08/18/17
17:45
Hot Stocks
Kansas City Southern director Henry Maier buys 3,000 shares »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

RXII

RXi Pharmaceuticals

$0.58

-0.02 (-3.36%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on RXi Pharmaceuticals »

RXi Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

WIN

Windstream

$1.98

0.06 (3.13%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Hot Stocks
Windstream CEO acquires 25,381 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$2.44

-0.22 (-8.27%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRN

Trinity Industries

$28.20

-0.03 (-0.11%)

17:25
08/18/17
08/18
17:25
08/18/17
17:25
Hot Stocks
ValueAct raises stake inTrinity Industries to 11% from 9.8% »

As of this date, ValueAct…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTN

Lpath

17:11
08/18/17
08/18
17:11
08/18/17
17:11
Hot Stocks
Breaking Hot Stocks news story on Lpath »

Stonepine Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$48.63

0.12 (0.25%)

17:08
08/18/17
08/18
17:08
08/18/17
17:08
Hot Stocks
Progressive CFO sells 50,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$172.57

-0.32 (-0.19%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Thermo Fisher director sells 11,318 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

SMBC

Southern Missouri Bancorp

$31.18

-0.05 (-0.16%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Southern Missouri Bancorp and Southern Missouri Bancshares to merge »

Southern Missouri Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:58
08/18/17
08/18
16:58
08/18/17
16:58
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ended advisory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ending…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says never had…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:56
08/18/17
08/18
16:56
08/18/17
16:56
Hot Stocks
Icahn no longer special advisor to President Trump on regulatory reform issues »

Carl Icahn, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:55
08/18/17
08/18
16:55
08/18/17
16:55
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:49
08/18/17
08/18
16:49
08/18/17
16:49
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$30.38

0.76 (2.57%)

16:48
08/18/17
08/18
16:48
08/18/17
16:48
Hot Stocks
Micron director sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 06

    Sep

INSY

Insys Therapeutics

$9.17

-0.11 (-1.19%)

16:42
08/18/17
08/18
16:42
08/18/17
16:42
Hot Stocks
Insys agrees to pay $4.45M to settle opioid marketing suit »

Illinois Attorney General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

16:34
08/18/17
08/18
16:34
08/18/17
16:34
Syndicate
Breaking Syndicate news story on Akari Therapeutics »

Akari Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMBA

Jamba

$9.11

-0.04 (-0.44%)

16:32
08/18/17
08/18
16:32
08/18/17
16:32
Hot Stocks
Jamba receives expected letter from Nasdaq »

Jamba, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIL

Hill International

$4.50

0.2 (4.65%)

16:31
08/18/17
08/18
16:31
08/18/17
16:31
Hot Stocks
Hill International receives NYSE notice regarding late Form 10-Q filing »

Hill International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$55.65

-0.47 (-0.84%)

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Periodicals
Target ends relationship with food startup Hampton Creek, Bloomberg says »

After an internal review,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Options
Preliminary option volume of 23.2M today »

Preliminary option volume…

NBEV

New Age Beverages

$3.51

-0.49 (-12.25%)

16:29
08/18/17
08/18
16:29
08/18/17
16:29
Hot Stocks
New Age Beverages director sells nearly 42,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

, ESV

Ensco

$4.28

0.12 (2.88%)

16:24
08/18/17
08/18
16:24
08/18/17
16:24
Hot Stocks
Atwood Oceanics, Ensco file proxy materials in connection with pending merger »

Ensco (ESV) and Atwood…

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

ESV

Ensco

$4.28

0.12 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$83.76

-0.1 (-0.12%)

16:23
08/18/17
08/18
16:23
08/18/17
16:23
Periodicals
Nestle faces potential fraud suit over Poland Spring marketing, WSJ says »

Nestle is facing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.